Pharmacogenomics of Hypertension and Preeclampsia: Focus on Gene-Gene Interactions

Autor(es)

Luizon, Marcelo R. ^{[1, 2]} ; Pereira, Daniela A. ^[1] ; Sandrim, Valeria C. ^[3]

Afiliação do(s) autor(es)

^[1] Univ Fed Minas Gerais, Inst Biol Sci, UFMG Grad Program Genet, Belo Horizonte, MG - Brazil

^[2] Fed Univ Minas Gerais UFMG, Inst Biol Sci, Dept Gen Biol, Belo Horizonte, MG - Brazil

^[3] Univ Estadual Paulista, Inst Biosci Botucatu, Dept Pharmacol, Botucatu, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: FRONTIERS IN PHARMACOLOGY; v. 9, FEB 28 2018.
• Citações Web of Science: 3

Resumo

Hypertension is a leading cause of cardiovascular mortality, but only about half of patients on antihypertensive therapy achieve blood pressure control. Preeclampsia is defined as pregnancy-induced hypertension and proteinuria, and is associated with increased maternal and perinatal mortality and morbidity. Similarly, a large number of patients with preeclampsia are non-responsive to antihypertensive therapy. Pharmacogenomics may help to guide the personalized treatment for non-responsive hypertensive patients. There is evidence for the association of genetic variants with variable response to the most commonly used antihypertensive drugs. However, further replication is needed to confirm these associations in different populations. The failure to replicate findings from single-locus association studies has prompted the search for novel statistical methods for data analysis, which are required to detect the complex effects from multiple genes to drug response phenotypes. Notably, genegene interaction analyses have been applied to pharmacogenetic studies, including antihypertensive drug response. In this perspective article, we present advances of considering the interactions among genetic polymorphisms of different candidate genes within pathways relevant to antihypertensive drug response, and we highlight recent findings related to gene-gene interactions on pharmacogenetics of hypertension and preeclampsia. Finally, we discuss the future directions that are needed to unravel additional genes and variants involved in the responsiveness to antihypertensive drugs. (AU)

• Processo FAPESP: 15/20461-8 - Papel do NRF2 e HO-1 em pré-eclâmpsia: estudo de polimorfismos genéticos, fatores circulantes e ensaios in vitro
• Beneficiário: Valeria Cristina Sandrim
• Modalidade de apoio: Auxílio à Pesquisa - Regular